Gu Jiawei, Cao Zhipeng, Niu Gengming, Ying Jianghui, Wang Hui, Jiang Hua, Ke Chongwei
Department of Plastic and Reconstructive Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Department of General Surgery, The Fifth People's Hospital of Shanghai, Fudan University, No. 801 Heqing Road, Minhang District, Shanghai, 200240, China.
Dig Dis Sci. 2025 Feb;70(2):622-637. doi: 10.1007/s10620-024-08813-y. Epub 2025 Jan 2.
The pathogenesis of hepatocellular carcinoma (HCC) emphasizes metabolic disorders. HCC patients showed abnormally low expression of Acyl-CoA dehydrogenase short chain (ACADS).
This study aimed to elucidate the clinical significance and mechanistic role of ACADS in HCC.
We investigated the expression patterns and significance of ACADS in HCC by analyzing multiple public databases and clinical samples (Chip data). Immunohistochemistry was employed to observe the expression levels of ACADS in HCC tissues. In vitro experiments involved silencing or overexpressing ACADS in HCC cell lines, with protein expression levels determined by Western blotting. Functional validation included CCK-8, Transwell, and scratch wound healing assays. TOPFlash and FOPFlash reporter gene assays, co-immunoprecipitation, and immunofluorescence were used to explore the interaction between ACADS and β-catenin.
ACADS was low expressed in HCC and was clinically associated with vascular invasion, TNM stage, and AFP levels. The low ACADS expression in HCC patients was negatively correlated with their survival. Overexpression of ACADS significantly suppressed the viability, migration, and invasive capacity of HCC cells, whereas silencing ACADS had the opposite effect. Mechanistically, co-immunoprecipitation experiments indicated that there was an interaction between ACADS and β-catenin. Overexpression of ACADS inhibited β-catenin activity and resulted in decreased nuclear β-catenin translocation and increased its cytoplasmic level. Immunofluorescence results also showed a decrease in β-catenin nuclear import following ACADS overexpression, whereas silencing ACADS led to an enhancement of its nuclear translocation.
ACADS emerges as a potentially valuable biomarker for HCC prognosis, exhibiting tumor-suppressive functions in HCC by participating in the regulation of β-catenin activity.
肝细胞癌(HCC)的发病机制强调代谢紊乱。HCC患者显示短链酰基辅酶A脱氢酶(ACADS)表达异常低。
本研究旨在阐明ACADS在HCC中的临床意义和机制作用。
我们通过分析多个公共数据库和临床样本(芯片数据)来研究ACADS在HCC中的表达模式和意义。采用免疫组织化学观察ACADS在HCC组织中的表达水平。体外实验包括在HCC细胞系中沉默或过表达ACADS,通过蛋白质印迹法测定蛋白质表达水平。功能验证包括CCK-8、Transwell和划痕伤口愈合试验。使用TOPFlash和FOPFlash报告基因试验、免疫共沉淀和免疫荧光来探索ACADS与β-连环蛋白之间的相互作用。
ACADS在HCC中低表达,并且在临床上与血管侵犯、TNM分期和甲胎蛋白水平相关。HCC患者中ACADS低表达与他们的生存率呈负相关。ACADS过表达显著抑制HCC细胞的活力、迁移和侵袭能力,而沉默ACADS则产生相反的效果。机制上,免疫共沉淀实验表明ACADS与β-连环蛋白之间存在相互作用。ACADS过表达抑制β-连环蛋白活性,并导致核β-连环蛋白转位减少和细胞质水平增加。免疫荧光结果还显示ACADS过表达后β-连环蛋白核内导入减少,而沉默ACADS导致其核转位增强。
ACADS成为HCC预后的一个潜在有价值的生物标志物,通过参与β-连环蛋白活性的调节在HCC中发挥肿瘤抑制功能。